Prothena Plc Valuation
| PRTA Stock | USD 6.26 0.21 3.25% |
At this time, the company appears to be undervalued. Prothena plc holds a recent Real Value of $16.76 per share. The prevailing price of the company is $6.26. Our model determines the value of Prothena plc from analyzing the company fundamentals such as Shares Outstanding of 53.83 M, operating margin of (23.19) %, and Return On Equity of -0.23 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Prothena Plc's price fluctuation is somewhat reliable at this time. Calculation of the real value of Prothena plc is based on 3 months time horizon. Increasing Prothena Plc's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Prothena Plc is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Prothena Stock. However, Prothena Plc's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.26 | Real 16.76 | Hype 6.38 | Naive 5.82 |
The real value of Prothena Stock, also known as its intrinsic value, is the underlying worth of Prothena plc Company, which is reflected in its stock price. It is based on Prothena Plc's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Prothena Plc's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Prothena plc helps investors to forecast how Prothena stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Prothena Plc more accurately as focusing exclusively on Prothena Plc's fundamentals will not take into account other important factors: Prothena Plc Total Value Analysis
Prothena plc is at this time anticipated to have valuation of (70.78 M) with market capitalization of 336.96 M, debt of 10.84 M, and cash on hands of 508.8 M. The negative valuation of Prothena Plc may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Prothena Plc fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(70.78 M) | 336.96 M | 10.84 M | 508.8 M |
Prothena Plc Investor Information
About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.77. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Prothena plc has Price/Earnings To Growth (PEG) ratio of 0.8. The entity recorded a loss per share of 2.05. The firm had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Prothena Plc's historical financial statements, Prothena plc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Prothena Plc Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prothena Plc has an asset utilization ratio of 24.7 percent. This suggests that the Company is making $0.25 for each dollar of assets. An increasing asset utilization means that Prothena plc is more efficient with each dollar of assets it utilizes for everyday operations.Prothena Plc Ownership Allocation
Prothena Plc owns a total of 53.83 Million outstanding shares. The majority of Prothena plc outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Prothena plc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Prothena Plc. Please pay attention to any change in the institutional holdings of Prothena plc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Prothena Plc Profitability Analysis
The company reported the previous year's revenue of 135.16 M. Net Loss for the year was (122.31 M) with loss before overhead, payroll, taxes, and interest of (71.28 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Prothena Plc's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Prothena Plc and how it compares across the competition.
About Prothena Plc Valuation
The stock valuation mechanism determines Prothena Plc's current worth on a weekly basis. Our valuation model uses a comparative analysis of Prothena Plc. We calculate exposure to Prothena Plc's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Prothena Plc's related companies.Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company was founded in 2012 and is based in Dublin, Ireland. Prothena Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Prothena Plc Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 53.8 M | |
| Forward Price Earnings | 64.1026 |
Complementary Tools for Prothena Stock analysis
When running Prothena Plc's price analysis, check to measure Prothena Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prothena Plc is operating at the current time. Most of Prothena Plc's value examination focuses on studying past and present price action to predict the probability of Prothena Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prothena Plc's price. Additionally, you may evaluate how the addition of Prothena Plc to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |